GLP-1 Origins & Biomarkers: Personalized Treatment Context

Last reviewed: June 3, 2026

Last updated: June 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Glucagon-like peptide-1 (GLP-1) originated from research into natural intestinal hormones that regulate blood sugar and appetite. Scientists discovered GLP-1 in the 1980s while studying gut physiology, eventually developing synthetic versions now used for weight management and diabetes. Understanding this natural foundation helps explain why GLP-1 works, yet individual responses remain highly variable.

Why this matters: not all patients respond identically to GLP-1 therapy, and genetic factors may partially explain these differences. PlexusDx focuses on precision wellness by helping patients understand their underlying predispositions before starting treatment. This context supports conversations with healthcare providers about which GLP-1 option and dosing strategy may align best with individual biology.

How GLP-1 Was Discovered and What It Does Naturally

GLP-1 is an incretin hormone produced by intestinal cells (L-cells) in response to nutrient intake. In the 1980s, researchers studying post-meal blood sugar regulation identified GLP-1 as a key signaling molecule that triggers insulin release and slows gastric emptying. This natural discovery became the foundation for synthetic GLP-1 receptor agonists used in modern medicine.

The natural hormone evolved to help manage energy intake and glucose stability. When you eat, GLP-1 signals your pancreas to release insulin proportionally, reduces appetite hormones, and slows stomach-to-intestine movement. Understanding this mechanism reveals why synthetic GLP-1 medications affect appetite, satiety, and metabolic rate—they mimic a natural biological pathway your body already uses daily.

Why Individual Response to GLP-1 Varies: The Genetic Context

Clinical research shows that GLP-1 therapy produces weight loss ranging from 5% to 22% body weight reduction, with significant variation between individuals. These differences are not random—genetic variants in GLP-1 receptor pathways, appetite-regulating genes, and fat-storage genes may influence how a patient's body responds to treatment. Biomarker analysis can help clarify this underlying variation.

Genetic Pathway	Gene/Variant	What It May Influence
GLP-1 Receptor Signaling	GLP1R rs6923761	May affect GLP-1 receptor sensitivity and medication response intensity
Appetite Regulation	GIPR rs1800437	May influence glucose-dependent insulinotropic peptide pathway activation
Energy Storage	FTO rs9939609	May affect baseline metabolic rate and fat oxidation patterns
Appetite Satiety	MC4R rs17782313	May influence melanocortin-4 receptor signaling in appetite control

From Natural Hormone to Therapeutic Tool: Clinical Translation

Pharmaceutical development transformed the natural GLP-1 hormone into longer-acting synthetic versions (exenatide, liraglutide, semaglutide, tirzepatide) that maintain therapeutic levels for days or weeks. This engineering overcomes the natural hormone's rapid breakdown, allowing once-weekly or daily dosing. Clinical trials have documented these synthetic versions' safety and efficacy across diabetes and weight management indications.

The move from nature to pharmaceutical formulation introduces both benefits and considerations. Synthetic GLP-1 agonists are reproducible, precisely dosed, and widely available—yet they bypass the body's natural regulatory feedback loops. This is why dose titration, provider monitoring, and individual biomarker context become important for optimizing outcomes and managing side effects.

Who Should Consider GLP-1 Therapy and What Biomarkers Reveal

GLP-1 therapy is appropriate for adults with type 2 diabetes, prediabetes, or weight management goals, depending on provider assessment and regulatory approval. However, candidacy depends on individual health status, concurrent medications, and personal goals. A healthcare provider should evaluate baseline health markers, medication interactions, and contraindications before starting any GLP-1 treatment.

Genetic biomarkers can support this evaluation by revealing predispositions in peptide signaling pathways. While genetic variants do not predict exact medication response, they may help explain baseline metabolism, appetite sensitivity, and fat-storage patterns. This information allows providers and patients to discuss realistic expectations and whether compounded or other formulations align with individual needs.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variants in four key pathways—GLP1R, GIPR, FTO, and MC4R—that influence natural GLP-1 signaling and appetite regulation. These variants may help provide context for why your baseline metabolism and appetite patterns are unique, supporting a more informed conversation about which GLP-1 formulation and dosing strategy might align with your biology. This test should be interpreted with a qualified healthcare provider as part of comprehensive treatment planning.

The genetic test reveals predispositions in peptide pathways, not exact medication response or pharmacokinetics. For example, certain FTO variants are associated with higher baseline metabolic rate variability, while GLP1R variants may relate to receptor sensitivity differences. Understanding these predispositions does not guarantee specific outcomes, but it contextualizes individual biology within the broader population response data, supporting more personalized treatment conversations.

Combined with your provider's clinical assessment, biomarker insights can inform decisions about which GLP-1 formulation (compounded semaglutide injection or oral, compounded tirzepatide injection or oral, or dual-compound GLP-Squared) and commitment tier may work best for your situation. This precision-wellness approach respects your unique biology while helping your provider titrate dose confidently—knowing that your dose may increase as needed, but your price remains flat across commitment tiers.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.